sibutramine has been researched along with Overweight in 28 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects." | 9.16 | Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 9.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 9.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| "Weight loss in response to sibutramine is highly variable." | 9.13 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. ( Braddock, AE; Burton, DD; Camilleri, M; Carlson, PJ; Clark, MM; Eckert, DJ; Graszer, KM; Grudell, AB; Kalsy, SA; Sweetser, S; Vazquez-Roque, MI; Zinsmeister, AR, 2008) |
| " Very few data exist regarding the effects of sibutramine on the mood of obese and overweight patients in general clinical samples." | 9.13 | Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Konitsiotis, S; Tsouli, S, 2008) |
| "A hypocaloric diet and a diet plus sibutramine both result in significant weight loss in overweight and obese women with PCOS." | 9.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "Assess body mass index (BMI) reduction through a multidisciplinary intervention with sibutramine in adolescents of military parents and examine characteristics and behavioral traits as predictors of successful weight loss." | 7.78 | Multidisciplinary intervention with sibutramine: assessing successful weight loss predictors in military adolescent dependents. ( Blankson, KL; Cabrera, JL; Cole, RE; Symons, JE; Wilks, EG, 2012) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 7.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "It is well established that sibutramine produces weight loss and is used frequently in women of childbearing age." | 7.76 | Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats. ( Carnietto, N; Cicogna, AC; Fernandes, GS; Francia-Farje, LA; Kempinas, Wde G; Silva, DS; Volpato, GT, 2010) |
| "During the initial 6-week sibutramine treatment period, systolic blood pressure decreased progressively with increasing weight loss in hypertensive subjects (-8." | 5.19 | Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. ( Caterson, ID; Coutinho, W; Espinoza, D; Finer, N; Gebski, V; Ivers, L; James, WP; Legler, UF; Seimon, RV; Sharma, AM, 2014) |
| "This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years." | 5.17 | Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects." | 5.16 | Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 5.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 5.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| "We used functional magnetic resonance imaging to explore brain responses to food images in overweight humans, examining independently the impact of a prescan meal ("satiety") and the anti-obesity drug sibutramine, a serotonin and noradrenaline reuptake inhibitor." | 5.14 | Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. ( Brooke, A; Bullmore, ET; Cambridge, VC; de Wit, S; Delafont, B; Farooqi, IS; Fletcher, PC; Miller, SR; Napolitano, A; Nathan, PJ; O'Rahilly, S; Skeggs, A, 2010) |
| "Weight loss in response to sibutramine is highly variable." | 5.13 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. ( Braddock, AE; Burton, DD; Camilleri, M; Carlson, PJ; Clark, MM; Eckert, DJ; Graszer, KM; Grudell, AB; Kalsy, SA; Sweetser, S; Vazquez-Roque, MI; Zinsmeister, AR, 2008) |
| " Very few data exist regarding the effects of sibutramine on the mood of obese and overweight patients in general clinical samples." | 5.13 | Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Konitsiotis, S; Tsouli, S, 2008) |
| "A hypocaloric diet and a diet plus sibutramine both result in significant weight loss in overweight and obese women with PCOS." | 5.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors." | 5.11 | Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. ( Gaciong, Z; Placha, G, 2005) |
| " Sibutramine has also been evaluated for use in overweight adolescents in 6 trials." | 4.84 | Pharmacotherapeutic options for overweight adolescents. ( Desilets, AR; Dunican, KC; Montalbano, JK, 2007) |
| "Assess body mass index (BMI) reduction through a multidisciplinary intervention with sibutramine in adolescents of military parents and examine characteristics and behavioral traits as predictors of successful weight loss." | 3.78 | Multidisciplinary intervention with sibutramine: assessing successful weight loss predictors in military adolescent dependents. ( Blankson, KL; Cabrera, JL; Cole, RE; Symons, JE; Wilks, EG, 2012) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 3.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "It is well established that sibutramine produces weight loss and is used frequently in women of childbearing age." | 3.76 | Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats. ( Carnietto, N; Cicogna, AC; Fernandes, GS; Francia-Farje, LA; Kempinas, Wde G; Silva, DS; Volpato, GT, 2010) |
| "With the rising prevalence of childhood obesity, pediatricians are increasingly called upon to treat clinically overweight children." | 2.49 | The clinical treatment of childhood obesity. ( Armstrong, SC; Dolinsky, DH; Kinra, S, 2013) |
| "The objective of this article was to estimate the risk of discontinuation due to adverse events in trials of orlistat, sibutramine and rimonabant." | 2.45 | Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. ( DeSantis, SM; Johansson, K; Neovius, K; Neovius, M; Rössner, S, 2009) |
| "For sibutramine, there is a rise in blood pressure and heart rate that may require discontinuation of the drug in a small percent of patients." | 2.44 | Drug treatment of the overweight patient. ( Bray, GA; Ryan, DH, 2007) |
| "In recent years, obesity has become a major public health problem in Western countries." | 2.43 | Medical strategies for weight loss in the overweight and obese patient. ( Bonanomi, G; Di Caro, S; Fernstrom, MH; Hamad, GG; Schauer, PR, 2006) |
| "Obesity and overweight are affecting increasing numbers of Canadians and have received considerable amounts of medical, governmental, and media attention in recent years." | 1.33 | Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004. ( Padwal, RS, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (50.00) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, HY | 1 |
| Park, S | 1 |
| Lee, JW | 1 |
| Ghotbi, AA | 1 |
| Køber, L | 2 |
| Finer, N | 4 |
| James, WP | 4 |
| Sharma, AM | 4 |
| Caterson, I | 1 |
| Coutinho, W | 4 |
| Van Gaal, LF | 2 |
| Torp-Pedersen, C | 3 |
| Andersson, C | 2 |
| Seimon, RV | 1 |
| Espinoza, D | 1 |
| Ivers, L | 1 |
| Gebski, V | 1 |
| Legler, UF | 1 |
| Caterson, ID | 3 |
| Grudell, AB | 1 |
| Sweetser, S | 1 |
| Camilleri, M | 1 |
| Eckert, DJ | 1 |
| Vazquez-Roque, MI | 1 |
| Carlson, PJ | 1 |
| Burton, DD | 1 |
| Braddock, AE | 1 |
| Clark, MM | 1 |
| Graszer, KM | 1 |
| Kalsy, SA | 1 |
| Zinsmeister, AR | 1 |
| Weeke, P | 1 |
| Fosbøl, EL | 1 |
| Brendorp, B | 1 |
| Van Gaal, L | 1 |
| Rode, RA | 2 |
| Johansson, K | 1 |
| Neovius, K | 1 |
| DeSantis, SM | 1 |
| Rössner, S | 1 |
| Neovius, M | 1 |
| Whitlock, EP | 1 |
| O'Connor, EA | 1 |
| Williams, SB | 1 |
| Beil, TL | 1 |
| Lutz, KW | 1 |
| Pöss, J | 1 |
| Böhm, M | 1 |
| Link, A | 1 |
| Francia-Farje, LA | 1 |
| Silva, DS | 1 |
| Volpato, GT | 1 |
| Fernandes, GS | 1 |
| Carnietto, N | 1 |
| Cicogna, AC | 1 |
| Kempinas, Wde G | 1 |
| Astrup, A | 1 |
| Maggioni, AP | 1 |
| Shepherd, GM | 1 |
| Renz, CL | 1 |
| Fletcher, PC | 1 |
| Napolitano, A | 1 |
| Skeggs, A | 1 |
| Miller, SR | 1 |
| Delafont, B | 1 |
| Cambridge, VC | 1 |
| de Wit, S | 1 |
| Nathan, PJ | 1 |
| Brooke, A | 1 |
| O'Rahilly, S | 1 |
| Farooqi, IS | 1 |
| Bullmore, ET | 1 |
| Koiou, E | 2 |
| Tziomalos, K | 2 |
| Dinas, K | 1 |
| Katsikis, I | 3 |
| Kalaitzakis, E | 2 |
| Delkos, D | 2 |
| Kandaraki, EA | 2 |
| Panidis, D | 3 |
| Vosnakis, C | 1 |
| Papazoglou, D | 1 |
| Restas, E | 1 |
| Papanas, N | 1 |
| Papatheodorou, K | 1 |
| Babouris, C | 1 |
| Glaros, D | 1 |
| Antonoglou, C | 1 |
| Maltezos, E | 1 |
| Cabrera, JL | 1 |
| Wilks, EG | 1 |
| Symons, JE | 1 |
| Blankson, KL | 1 |
| Cole, RE | 1 |
| Dolinsky, DH | 1 |
| Armstrong, SC | 1 |
| Kinra, S | 1 |
| Gaciong, Z | 1 |
| Placha, G | 1 |
| Padwal, RS | 1 |
| Dietz, WH | 1 |
| Di Caro, S | 1 |
| Hamad, GG | 1 |
| Fernstrom, MH | 1 |
| Schauer, PR | 1 |
| Bonanomi, G | 1 |
| Bray, GA | 1 |
| Ryan, DH | 1 |
| Kiortsis, DN | 1 |
| Tsouli, S | 1 |
| Filippatos, TD | 1 |
| Konitsiotis, S | 1 |
| Elisaf, MS | 1 |
| Dunican, KC | 1 |
| Desilets, AR | 1 |
| Montalbano, JK | 1 |
| Suter, PM | 1 |
| Kolyvanos, NU | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Litvan, L | 1 |
| Alcoverro-Fortuny, O | 1 |
| Florakis, D | 1 |
| Diamanti-Kandarakis, E | 1 |
| Nassis, GP | 1 |
| Karkanaki, A | 1 |
| Georgopoulos, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event[NCT00234832] | Phase 3 | 10,777 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients[NCT00433641] | Phase 4 | 181 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| ADAPT+: Optimizing an Intervention to Promote Healthy Behaviors in Rural, Latino Youth With Obesity and Their Parents, Using Mindfulness Strategies[NCT04800432] | 108 participants (Actual) | Interventional | 2021-03-06 | Active, not recruiting | |||
| Exergaming for Health: Impact of a Community-Based Active Video Gaming Curriculum in Pediatric Weight Management[NCT02436330] | 84 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| Effect of Personal Activity Trackers on Weight Loss in Children Enrolled in a Comprehensive Behavioral Family Lifestyle Intervention (CBFLI) Program[NCT03215641] | 200 participants (Anticipated) | Interventional | 2015-08-31 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For each subject who died, the time to death was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 418 |
| Randomized Placebo | 404 |
For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 200 |
| Randomized Placebo | 159 |
For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 127 |
| Randomized Placebo | 95 |
This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 927 |
| Randomized Placebo | 856 |
For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 11 |
| Randomized Placebo | 7 |
For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 223 |
| Randomized Placebo | 229 |
For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Intent-to-treat population | |
| CV + DM Randomized to Placebo | 346 |
| CV + DM Randomized to Sibutramine | 403 |
| CV Only Randomized to Placebo | 66 |
| CV Only Randomized to Sibutramine | 77 |
| DM Only Randomized to Placebo | 77 |
| DM Only Randomized to Sibutramine | 79 |
| Randomized Placebo | 490 |
| Randomized Sibutramine | 561 |
Activity will be measured by pedometers (number of steps) during week 1 and week 24 for both groups. Subjects used the Yamax 200 pedometer to count the steps they took over 1 weeks time. (NCT02436330)
Timeframe: Change from week 1 to week 24
| Intervention | steps (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -6626 |
| Didactic Health Teaching | -9059.5 |
Change in after school screen time (reported out as fraction of 1 hour) will be measured by subject response on questionnaire taken at baseline and at 6 months for both groups. After school screen time was defined as the amount of time spent on any screen, on the average weekday afternoon/evening, including: watching television, computer use (laptop, desk top, tablet) or playing video games on the television or other hand held device. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | hours (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.7589 |
| Didactic Health Teaching | 0.188 |
All subjects were asked to dress in light athletic clothing and have their weight and height measured at baseline (the first group session) and at 6 months. Research assistants were trained using guidelines from the National Health and Nutrition Examination Survey (NHANES) Anthropometry Procedures Manual and demonstrated accurate measures on 3 separate children. The Seca 217 portable stadiometer was used for all height measurements and the HealthOMeter 844 KL scale was used for all weight measurements. BMI z-scores were calculated using software available from the Children's Hospital of Philadelphia Research Institute (http://stokes.chop.edu/web/zcore). (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | z-score (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.057 |
| Didactic Health Teaching | 0.005 |
Measure was only taken on the subjects who participated in the Intervention group (exergaming combined with didactic teaching). (NCT02436330)
Timeframe: Change from baseline BMI z-score at 1 year
| Intervention | z-score (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.0775 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total % dietary carbohydrates is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | percentage of carbohydrates (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 2.10 |
| Didactic Health Teaching | -5.12 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total %dietary fat intake per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | percentage of fat (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -1.25 |
| Didactic Health Teaching | 3.00 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total number of fruit servings per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | Servings (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.13255 |
| Didactic Health Teaching | 0.663 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total number of sugar sweetened beverages per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | servings (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -2.572 |
| Didactic Health Teaching | -3.2374 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total number of vegetable servings per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | servings (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 0.0078 |
| Didactic Health Teaching | 0.8248 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total kcal/kg/day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | kcal/day (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -292.92 |
| Didactic Health Teaching | -45 |
"The experimental group will answer a questionnaire at the end of the 6 month study period, measuring the importance of specific components of the curriculum and motivators which influenced enrollment and compliance with participation. Of interest is measuring the influence of the exergaming curriculum as compared to these other factors. This is a 16-item, 3-point Likert-scale (1 = least important and 3 = most important) questionnaire created specifically for this study. Results were reported based on % of participants rating 3 ,most important, for each curriculum component." (NCT02436330)
Timeframe: 6 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Exergaming and Didactic Health Teaching | 71 |
(NCT02436330)
Timeframe: Change from 6 month Heart rate at 1 year
| Intervention | beats per minute (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 2.7407 |
(NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | beats per minute (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -9.9 |
| Didactic Health Teaching | -7.0 |
Change in Saturday screen time (reported out as fraction of an hour) will be measured by subject response on questionnaire taken at baseline and at 6 months for both groups. Saturday screen time was defined as the amount of time spent on any screen, on an average Saturday, including: watching television, computer use (laptop, desk top, tablet) or playing video games on the television or other hand held device. (NCT02436330)
Timeframe: Change in hours from baseline at 6 months
| Intervention | hours (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -1.4 |
| Didactic Health Teaching | -0.3438 |
CY-PSPP questionnaire was completed by participants in both groups at baseline and at 6 months. Change in the Global Self-worth scores, which was 1 of 6 sub-domains, is analyzed. This sub-domain contains 6 questions with responses ranging from 1-4 for each question with 1 being the minimum and 4 being the maximum (best) score. The sub-domain score is then calculated as the mean of the 6 responses (minimum to maximum of 1 to 4).The change in score from baseline to 6 months was compared. (NCT02436330)
Timeframe: Change from baseline to 6 months
| Intervention | scores on a scale (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.238 |
| Didactic Health Teaching | -0.523 |
CY-PSPP questionnaire was completed by participants in both groups at baseline and at 6 months. Change in the Physical Self-worth scores, which was 1 of 6 sub-domains, is analyzed. This sub-domain contains 6 questions with responses ranging from 1-4 for each question with 1 being the minimum and 4 being the maximum (best) score. The sub-domain score is then calculated as the mean of the 6 responses (minimum to maximum of 1 to 4).The change in score from baseline to 6 months was compared. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | scores on a scale (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.218 |
| Didactic Health Teaching | -0.5 |
The shuttle run was completed again by participants in the Experimental group at 1 year. The shuttle run is a standardized field assessment that requires participants to run 20 meters within sequentially shortened time frames of recorded beeps. (NCT02436330)
Timeframe: Change in number from 6 month shuttle run at 1 year
| Intervention | number of runs (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 0.10 |
The shuttle run was completed by participants at baseline (session 1) and at 6 months. The shuttle run is a standardized field assessment that requires participants to run 20 meters within sequentially shortened time frames of recorded beeps. (NCT02436330)
Timeframe: Change in number from baseline shuttle run at 6 months
| Intervention | number of runs (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 0.213 |
| Didactic Health Teaching | -0.00085 |
(NCT02436330)
Timeframe: Change from 6 month Systolic BP at 1 year
| Intervention | mmHg (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 3.5185 |
(NCT02436330)
Timeframe: Change from baseline Systolic BP at 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 1 |
| Didactic Health Teaching | 0 |
(NCT02436330)
Timeframe: Change from 6 month waist circumference at 1 year
| Intervention | cm (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 1.52 |
(NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | cm (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.50 |
| Didactic Health Teaching | -0.51 |
7 reviews available for sibutramine and Overweight
| Article | Year |
|---|---|
Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Medication Adherence; Odd | 2009 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
The clinical treatment of childhood obesity.
Topics: Adolescent; Bariatric Surgery; Behavior Therapy; Child; Child, Preschool; Combined Modality Therapy; | 2013 |
Medical strategies for weight loss in the overweight and obese patient.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Body Mass Index; Cyclobutanes; Exercise | 2006 |
Drug treatment of the overweight patient.
Topics: Animals; Anti-Obesity Agents; Clinical Trials, Phase II as Topic; Cyclobutanes; Humans; Lactones; Ob | 2007 |
Pharmacotherapeutic options for overweight adolescents.
Topics: Adolescent; Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Hypoglycemic Agents | 2007 |
[Obesity in adults].
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobut | 2007 |
11 trials available for sibutramine and Overweight
| Article | Year |
|---|---|
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Topics: Aged; Cardiovascular Diseases; Clinical Protocols; Cyclobutanes; Diabetes Mellitus, Type 2; Female; | 2013 |
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet | 2014 |
A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
Topics: Adult; Appetite Depressants; Body Composition; Cyclobutanes; Feeding Behavior; Female; Gastric Empty | 2008 |
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Topics: Aged; Appetite Depressants; Bilirubin; Biomarkers; Cardiovascular Diseases; Confounding Factors, Epi | 2009 |
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum.
Topics: Adiposity; Adult; Amygdala; Appetite Depressants; Basal Ganglia; Body Weight; Brain; Cyclobutanes; D | 2010 |
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine.
Topics: Alleles; Appetite Depressants; Body Composition; Body Mass Index; Body Weight; Cyclobutanes; Female; | 2012 |
Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobutanes; Dia | 2005 |
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
Topics: Adult; Affect; Analysis of Variance; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cyc | 2008 |
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Topics: Adolescent; Adult; Androgens; Anthropometry; Appetite Depressants; Blood Glucose; Body Fat Distribut | 2008 |
10 other studies available for sibutramine and Overweight
| Article | Year |
|---|---|
Positive association between the changes in chemerin and adiponectin levels after weight reduction.
Topics: Adiponectin; Adult; Anti-Obesity Agents; Appetite Depressants; Biomarkers; Body Mass Index; Chemokin | 2017 |
[32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine].
Topics: Adult; Appetite Depressants; Cyclobutanes; Female; Humans; Medical History Taking; Myocardial Infarc | 2010 |
Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats.
Topics: Animals; Appetite Depressants; Cyclobutanes; Embryo Loss; Female; Overweight; Pregnancy; Rats; Rats, | 2010 |
Drug management of obesity--efficacy versus safety.
Topics: Anti-Obesity Agents; Benzazepines; Contraindications; Cyclobutanes; Drug Approval; Fenfluramine; Hum | 2010 |
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformi | 2011 |
Multidisciplinary intervention with sibutramine: assessing successful weight loss predictors in military adolescent dependents.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Combined Modality The | 2012 |
Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004.
Topics: Adult; Aged; Anti-Obesity Agents; Canada; Cyclobutanes; Drug Prescriptions; Female; Humans; Lactones | 2005 |
Keeping weight-loss drugs in perspective. If you're dangerously overweight, diet pills may help--but not without major lifestyle changes.
Topics: Anti-Obesity Agents; Cyclobutanes; Eating; Female; Humans; Lactones; Obesity; Orlistat; Overweight; | 2006 |
What constitutes successful weight management in adolescents?
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cyclobutanes; Female; | 2006 |
Sibutramine and psychosis.
Topics: Appetite Depressants; Brief Psychiatric Rating Scale; Cyclobutanes; Dose-Response Relationship, Drug | 2007 |